Lutetium Oxodotreotide not checked

Sinotau Pharmaceutical Group · 177Lu-DOTA0-Tyr3-Octreotate

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Advanced Neuroendocrine Neoplasm
Main trialPhase 2/3
“This is a multicenter, single-arm, two-part study designed to evaluate the safety and efficacy of Lutetium \[177Lu\] Oxyoctreotide Injection in patients with inoperable, locally advanced or metastatic, progressive, advanced somatostatin receptor (SSTR) positive neuroendocrine neoplasms (NEN) other than grade G1/G2 gastroenteropancreatic neuroendocrine tumors (GEP-NET) and Neuroendocrine Carcinoma(NEC).”In the company’s words, NCT06398444 on ClinicalTrials.gov
Other names
177Lu-DOTA0-Tyr3-Octreotate

Coming up1

Changes2

Last 90 days

Trials2

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting 1 Jun 2027 A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Phase 3Completed 26 Jun 2025 A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Lutetium Oxodotreotide

Following is part of Solo: you see every change to Lutetium Oxodotreotide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in